Navigation Links
Results of DUTCH PEERS (TWENTE II) trial reported at TCT 2013
Date:10/31/2013

ion (age 63.910.8 years, range 21󈟇 years; 73.0 percent male) was an "all-comers" population comprising 58.6 percent of patients with acute coronary syndromes (20.4 percent of all patients presented with an acute ST-elevation myocardial infarction). Of all 2,371 lesions, 65.7 percent were ACC/AHA lesion type B2/C. Follow-up data for 99.9 percent of the randomized patients were obtained.

TVF occurred in 6.1 percent (55/905) patients assigned to zotarolimus-eluting stents and 5.2 percent (47/905) assigned to everolimus-eluting stents. Non-inferiority of the zotarolimus-eluting stent was confirmed with an absolute risk difference of 0.88 percent (non-inferiority p-value = 0.006). There was also no significant between-group difference in individual components of the primary endpoint and other secondary clinical endpoints.

In both stent groups, definite-or-probable stent thrombosis rates were low. Definite-or-probable stent thrombosis rates were 0.6 percent (5/905) in the zotarolimus stent and 0.9 percent (8/905) in the everolimus stent (p value=0.40). Notably, there was no definite stent thrombosis beyond three months from stenting, reaffirming the safety of newer generation DES platforms.

"The clinical outcome of this trial was excellent particularly when considering its high proportion of complex patients with acute myocardial infarction at presentation and may represent a challenging touchstone of novel stents and scaffolds," said Clemens von Birgelen, MD PhD, the principal investigator of the trial. Dr. von Birgelen is Co-Director of the Department of Cardiology at Thoraxcentrum Twente and Professor of Cardiology at University of Twente in the Netherlands.

"Both permanent polymer-based stents were similarly efficacious and safe in treating all-comers with an excellent clinical outcome."


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Page: 1 2

Related medicine news :

1. False-Positive Mammogram Results May Turn Out Not to Be: Study
2. Good intentions bring mixed results for Haitis disabled people
3. Presentation of 1-year IVAN and 2-year CATT study results
4. Groundbreaking Nigeria summit results in major commitment to reduce child deaths
5. Surprising results for use of dialysis for kidney failure in developing world
6. Stem Cell Study Shows Promising Results Against Heart Failure
7. Automated insulin dosage titration system demonstrates positive clinical study results
8. Quality of care, other issues may cause worse results in black prostate cancer surgery patients
9. Tight Blood-Sugar Control Shows Mixed Results for Health of Kidneys: Study
10. ACP-New York State Chapter partnership results in patient safety organization recognition
11. Long-term testosterone treatment for men results in reduced weight and waist size
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... 2015 Mew and Company, a Vancouver ... now provide business consulting services in addition to a ... planning and succession planning. Company finances are a complicated ... On top of this, complex Canadian tax laws can ... As a result, Mew and Company works to advise ...
(Date:2/28/2015)... 2015 The Mesothelioma Applied Research ... at the International Symposium on Malignant Mesothelioma on Monday, ... the Hyatt Regency Bethesda in Bethesda, Maryland. The following ... and commitment to the mission to cure mesothelioma. , ... be presented to Miriam Ratner. Miriam runs the Meso ...
(Date:2/28/2015)... 28, 2015 A case management conference ... that have been filed by law firms including Bernstein ... in March, the Firm notes. , According to ... in the federal litigation will meet on March 13, ... prescription therapy treatments designed to raise levels of the ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 The noted ... of Facial Surgery was recently featured in the January/February ... the magazine, Dr. David Ellis was featured in an ... the various cosmetic enhancements that Kim Cattrall has possibly ... , “Her forehead is smooth without horizontal lines or ...
(Date:2/28/2015)... Memphis, TN: MedixSafe has retracted a previous announcement ... reader named Guardian 2. The correct product name ... scanner that significantly increases the complexity of security ... scanner provides fast and easy access for both ... lockers with Vanguard technology tracks inventory by ...
Breaking Medicine News(10 mins):Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 4Health News:Dr. David Ellis Featured In Elevate Magazine 2Health News:New Name Announced For Newest MedixSafe Readers – MedixSafe Vanguard 2
... of oral steroid treatment decreases the risk of rheumatoid arthritis ... regardless of when in the course of the disease the ... observed if the steroids were taken for less than a ... treatment in rheumatoid arthritis have been a subject of much ...
... was brought to lime light when a hospital in Bangkok when ... of a 2-year old baby. The baby was suffering from ... disease and lived because of a transplant of umbilical cord blood. ... develop into a wide range of different blood cells which can ...
... Urging the medical community to develop 'much cheaper' drugs to ... said the available first and second line treatment of the ... man in the country. ,Stating that the Indian companies ... first and second line HIV drugs, Kalam said: "Even this ...
... Entertainment giant Sony has apologised to the Church of England ... game, a spokesman for the church said Friday. ... Cathedral in north-west England, saying they had not intended to ... game "Resistance: Fall of Man," he added. ...
... in 1991, an expert in the ancient art of Ikebana flower ... most of the 16 years since, Midori Yamada has taught Russians ... vases -- as attempted coups, and spectacular booms and busts played ... is very strict, each flower has its laws," she said. "With ...
... of the public health system in the US keeps tumbling ... stated that adults// with serious mental illness and treated in ... ,The gap has widened since the early '90s ... 15 years. ,"We're going in the wrong direction ...
Cached Medicine News:Health News:Long-term Oral Steroid Therapy Decreases Lymphoma Risk in Rheumatoid Arthritis 2Health News:Stem Cells- a Miraculous Boon 2Health News:Japanese Flower Art Helps Calm a Frantic Moscow 2Health News:Major Mental Disorders Cut Life Span by Ten to Fifteen Years 2
(Date:2/27/2015)... 27, 2015 An aggressive campaign to reduce ... rate of infection with a dangerous drug-resistant bacteria at ... Clostridium difficile, or C.diff, is a bacterium that can ... the colon. A recent article in the New England ... in the United States " asserts ...
(Date:2/27/2015)... Mass. , Feb. 27, 2015   Synageva ... ), a biopharmaceutical company developing therapeutic products for ... Disorders™ (NORD™), the European Organisation for Rare Diseases™ ... the world in observing Rare Disease Day. ... year, patient organizations, industry, and other participants conduct ...
(Date:2/27/2015)... N.J., Feb. 27, 2015  PTC Therapeutics, Inc. (NASDAQ: ... and reported financial results for the fourth quarter and ... "2014 was a transformative year for PTC. We are ... and developing RNA-targeted therapies in the rare disease space," ... Therapeutics, Inc. "We are proud to bring the first ...
Breaking Medicine Technology:Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11
... data for Perforomist(TM) Solution presented at,International CHEST ... from a Phase IIIb,clinical trial demonstrate that ... prolonged bronchodilation,and increased patient satisfaction compared to ... presented today in Philadelphia,at CHEST 2008, the ...
... oral ADHD stimulant medication with published data,demonstrating symptom ... clinical,study, CHICAGO, Oct. 29 Shire plc ... today announced,results from a 13-hour analog classroom study ... Attention Deficit Hyperactivity Disorder (ADHD). In this,study, researchers ...
Cached Medicine Technology:Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI 2Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI 3Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI 4Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI 5Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI 6Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD 2Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD 3Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD 4Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD 5Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD 6Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD 7
... Mo Bio Vortex Adapter in conjunction with the ... Using the Mo Bio Vortex Adapter is ... Fast Prep machines which offer the same technology. ... centrifuge tubes at one time and will fit ...
Use the Mo Bio Vortex Adapter in conjunction with the Vortex Genie 2 for rapid bead beating procedures. Using the Mo Bio Vortex Adapter is an inexpensive alternative to other bead beating and Fast Pr...
... with Vacuum Controller V-800 and water-cooled secondary condenser ... Compact Housing Model V-500 is ... handle most vacuum applications. Applications ... rotary evaporators Laboratory vacuum source for ...
... Combines BchiVac V-500 with Vacuum Controller V-800 ... vacuum levels from Model V-500 ... to handle most vacuum applications. Applications ... two rotary evaporators Laboratory vacuum source ...
Medicine Products: